Wells Fargo added Penumbra (PEN) to the firm’s Q4 2025 Tactical Ideas List. The firm says Penumbra has two important potential near-term catalysts, namely STORM-PE at TCT and VIVA; and FDA approval of Thunderbolt. Each has the potential to expand TAM, increase penetration and drive share gain, Wells adds. Penumbra management sounded positive on the second half of 2025 outlook. The firm has an Overweight rating on the name with a price target of $290 on the shares.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PEN:
- Positive Outlook for Penumbra Amid Promising STORM PE Trial and Expanding Pulmonary Embolism Market
- Positive Outlook on Penumbra’s Stock Driven by Ruby XL’s Market Impact and Efficiency Gains
- Elf Beauty downgraded, Zscaler upgraded: Wall Street’s top analyst calls
- Penumbra initiated with an Outperform at Evercore ISI
- Penumbra Appoints Shruthi Narayan as New President